Johnson Pharmacare Limited has announced that its board of directors will meet on Wednesday, May 27, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The meeting is scheduled to take place at the company's registered office located at Office No. 4-D, Fourth Floor Vardan Tower, Lakhudi Circle, Near Sardar Patel Stadium, Navrangpura, Ahmedabad City, Gujarat, India, 380009.

The primary agenda for the meeting is the review and approval of the company's financial performance for the specified period. In compliance with Regulation 29 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, the company has provided prior intimation regarding this board meeting.

In conjunction with the upcoming financial results, the company has closed its trading window. The window shut on April 1, 2026, and will remain closed until 48 hours after the declaration of the audited financial results for the quarter and year ended March 31, 2026. This measure is intended to prevent insider trading during the sensitive period surrounding the announcement.

Board Meeting Details

The board may also discuss any other matters with the prior permission of the Chairperson. The intimation was signed by Nand Kishor Ray, Additional Director, on behalf of the board of directors.

Johnson pharmacare Limited has strengthened its board of directors with two new appointments, as announced in a regulatory filing dated April 17, 2026. The pharmaceutical company's board meeting approved these strategic additions to enhance its leadership structure and operational capabilities.

Board Meeting Details

The board of directors convened on Friday, April 17, 2026, from 5:15 p.m. to 5:45 p.m. to deliberate on the director appointments. The meeting was conducted in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically under Regulation 30 requirements.

New Director Appointments

The board approved two significant appointments effective immediately:

Director Profiles and Qualifications

Mr. Nand Kishore Ray brings experience to the board as the newly appointed Non-Executive & Non-Independent Director. Born on January 1, 1956, he is a graduate and son of Mr. Kalewar Ray. His appointment adds non-executive oversight to the company's governance structure.

Mr. Dheeraj Kumar joins as an Executive Director, bringing operational leadership to the board. Born on January 1, 2005, he is also a graduate and son of Mr. Nand Kishor Ray. His executive role will involve direct participation in the company's day-to-day management and strategic decisions.

Regulatory Compliance

Both appointees have submitted declarations of non-debarment as required under SEBI regulations. The declarations confirm that:

• Neither director is debarred from accessing capital markets
• No orders have been passed by SEBI or other authorities preventing them from holding director positions
• Both meet the eligibility criteria for their respective board positions

Corporate Governance Enhancement

These appointments reflect Johnson Pharmacare Limited's commitment to strengthening its corporate governance framework. The addition of both executive and non-executive directors provides a balanced approach to board composition, ensuring effective oversight while maintaining operational agility in the pharmaceutical sector.